Dicerna Pharmaceuticals Average Assets vs Enterprise Value Analysis

DRNA -- USA Stock  

Quarterly Earning Report: November 4, 2019  

Dicerna Pharmaceuticals financial indicator trend analysis is much more than just examining Dicerna Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dicerna Pharmaceuticals is a good investment. Please check the relationship between Dicerna Pharmaceuticals Average Assets and its Enterprise Value accounts. Additionally see Investing Opportunities.

Average Assets vs Enterprise Value

Accounts Relationship

Average Assets vs Enterprise Value

Significance: Strong Relationship

Average Assets diversification synergy
Overlapping area represents amount of trend that can be explained by analyzing historical patterns of Dicerna Pharmaceuticals Average Assets account and Enterprise Value

Correlation Coefficient

Relationship DirectionPositive 
Relationship StrengthSignificant

Average Assets

Average asset value for the period used in calculation of Return on Average Equity and Return on Average Assets; derived from [Assets].

Enterprise Value

Enterprise Value (or EV) is usually referred to as Dicerna Pharmaceuticals theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Dicerna Pharmaceuticals debt, but would also pocket its cash. Enterprise Value is more accurate representation of Dicerna Pharmaceuticals value than its market capitalization because it takes into account all of Dicerna Pharmaceuticals existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as [MarketCap] plus [DebtUSD] minus [CashnEqUSD].
Search macroaxis.com